Want to see IN:JBCHEPHARM full AI Analyst Report?
JBCHEPHARM Stock Chart & Stats
₹1847.80
-₹0.05(>-0.01%)
At close: 4:00 PM EST
₹1847.80
-₹0.05(>-0.01%)
Day’s Range― - ―
52-Week Range₹1,603.05 - ₹2,509.40
Previous CloseN/A
Volume153.25K
Average Volume (3M)2.67K
Market Cap
₹387.31B
Enterprise Value₹318.72K
Total Cash (Recent Filing)₹12.21B
Total Debt (Recent Filing)₹36.00M
Price to Earnings (P/E)53.4
Beta0.56
Next Earnings
Aug 06, 2026EPS Estimate
13.55Next Dividend Ex-DateN/A
Dividend Yield0.91%
Share Statistics
EPS (TTM)45.24
Shares Outstanding160,558,700
10 Day Avg. Volume4,569
30 Day Avg. Volume2,671
Financial Highlights & Ratios
PEG Ratio7.16
Price to Book (P/B)7.80
Price to Sales (P/S)7.82
P/FCF Ratio51.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)60.29
Revenue Forecast (FY)₹47.09B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetNear-negligible debt and a conservative balance sheet provide durable financial flexibility. This lowers bankruptcy and refinancing risk, supports steady capex and R&D funding, and enables opportunistic M&A or market investments without pressuring cash flow, aiding multi‑quarter resilience.
Multi-year Revenue ExpansionSustained top‑line growth across multiple years indicates expanding market penetration and scale, reinforcing distribution and pricing power in branded generics and exports. That scale supports operating leverage and product investment, underpinning durable competitive positioning over months.
Recent Strong Cash GenerationA rebound to robust free cash flow and consistent operating cash flow improve internal funding for growth, dividends, and deleveraging. Reliable cash generation enhances strategic optionality and reduces dependence on external financing over a 2–6 month horizon and beyond.
Bears Say
Slowing Revenue GrowthA shift from stronger multi‑year expansion to low single‑digit growth signals rising maturity or competitive pressure in core markets. Slower revenue momentum can limit operating leverage, constrain margin expansion and reduce the pace of investment returns for the coming quarters.
Margin VolatilityMaterial swings in gross and operating margins imply sensitivity to product mix, input costs, or pricing pressure. Persistent margin volatility undermines earnings predictability, complicates capital allocation and forecasting, and raises execution risk for sustaining profitability long term.
Historical Free Cash Flow SwingsEpisodes of materially negative free cash flow reflect working capital or capex volatility. If recurring, such swings can strain liquidity, limit shareholder returns, and force external financing in adverse periods, reducing strategic flexibility over medium-term planning horizons.
JB Chemicals & Pharmaceuticals Ltd. News
JBCHEPHARM FAQ
What was JB Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
JB Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹1603.05 and its highest was ₹2509.40 in the past 12 months.
What is JB Chemicals & Pharmaceuticals Ltd.’s market cap?
JB Chemicals & Pharmaceuticals Ltd.’s market cap is ₹387.31B.
When is JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were JB Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
JB Chemicals & Pharmaceuticals Ltd. released its earnings results on May 11, 2026. The company reported ₹7.7 earnings per share for the quarter, missing the consensus estimate of ₹9.9 by -₹2.2.
Is JB Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts JB Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does JB Chemicals & Pharmaceuticals Ltd. pay dividends?
JB Chemicals & Pharmaceuticals Ltd. pays a Semiannually dividend of ₹9.3 which represents an annual dividend yield of 0.91%. See more information on JB Chemicals & Pharmaceuticals Ltd. dividends here
What is JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate is 13.55.
How many shares outstanding does JB Chemicals & Pharmaceuticals Ltd. have?
JB Chemicals & Pharmaceuticals Ltd. has 160,558,700 shares outstanding.
What happened to JB Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
JB Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹7.7 in its last earnings report, missing expectations of ₹9.9. Following the earnings report the stock price went up 2.6%.
Which hedge fund is a major shareholder of JB Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JBCHEPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JB Chemicals & Pharmaceuticals Ltd.
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
Eris Lifesciences Ltd
―
IPCA Laboratories Limited
―
Wockhardt Limited
―